MSD and Erasca collaborate on clinical trial for RAS-mutant tumours

MSD and Erasca have collaborated to assess ERAS-0015 in combination with Keytruda in patients with RAS-mutant solid tumours. In the ongoing AURORAS-I Phase I trial, Erasca is evaluating ERAS-0015 in patients with RAS-mutant solid tumours. Erasca seeks to determine if pan-RAS inhibition with ERAS-0015 and pembrolizumab can improve therapy and limit resistance development. Credit: Gorodenkoff / Shutterstock.com. Merck & Co (MSD) and Erasca have entered a clinical trial collaboration and supply agreement to assess ERAS-0015 in combination with Keytruda (pembrolizumab) in patients with rat sarcoma virus (RAS)-mutant solid tumours. The AURORAS-I proof-of-concept study, sponsored by Erasca, will be supported by…

Source: Clinical Trials Arena